Drug Trial Radar · NCT05819398
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
209
Actual
Start
Apr 17, 2023
Primary completion
Aug 1, 2024
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS. People who have previously taken specific medicines such as immunosuppressive biologics other than Tumor necrosis factor (TNF) inhibitors cannot take part. This study has 2 parts. In Part 1, participants are divided into 4 groups of almost equal size. 3 groups get different doses of spesolimab, 1 group gets placebo. All participants get injections into a vein or under the skin. Placebo injections look like spesolimab injections, but do not contain any medicine. Every participant has an equal chance of being in each group. In the beginning, participants get the study medicine every week and later every 2 weeks. After 4 months, participants in the placebo group switch to spesolimab treatment. In Part 2, participants are divided into 2 groups. One group gets a suitable dose of spesolimab that was found in Part 1 of the study. The other group gets placebo. After 4 months, participants in the placebo group switch to spesolimab treatment. Participants join only one of the two parts. They are in the study for about 1 year. During this time, they visit the study site in the beginning every week and later every 2 weeks. Some of the visits can be done at the participant's home instead of the study site. The doctors regularly check participants' HS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.
Conditions
- Hidradenitis Suppurativa
Interventions
Spesolimab i.v.Drug
Weekly dose of spesolimab via i.v. for 4 weeks.
Spesolimab s.c.Drug
Weekly s.c. dose of spesolimab for 4 weeks (3 weeks for Placebo), and maintenance s.c. dose of spesolimab every two weeks until the end of the treatment.
Placebo matching Spesolimab i.v.Drug
Weekly dose of placebo via i.v. for 4 weeks.
Placebo matching Spesolimab s.c.Drug
Weekly s.c. dose of placebo for 4 weeks, and once every 2 weeks for the following 7 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 8Time frame: The MMRM model incorporates dT count from baseline (Week 0), Week 2, Week 4, Week 6 and Week 8. The data represent the Least Squares Means at Week 8.
Locations
162 sites in 35 countries. Site status is shown where the registry gives one.
First OC Dermatology
Fountain Valley, California
Dermatology Research Associates
Los Angeles, California
Integrative Skin Science and Research-Sacramento-69402
Sacramento, California
Clinical Trials Research Institute
Thousand Oaks, California
Ziaderm Research
North Miami Beach, Florida
ForCare Clinical Research, Inc.
Tampa, Florida
Olympian Clinical Research-Tampa-69560
Tampa, Florida
Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995
Indianapolis, Indiana
Skin Sciences, PLLC
Louisville, Kentucky
University of Michigan Health System
Ann Arbor, Michigan
Oakland Hills Dermatology, PC
Auburn Hills, Michigan
Skin Specialists, P.C.
Omaha, Nebraska
AXIS Clinicals
Fargo, North Dakota
Unity Clinical Research
Oklahoma City, Oklahoma
University of Pennsylvania
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Palmetto Clinical Trial Services
Greenville, South Carolina
Center for Clinical Studies-Houston-58806
Houston, Texas
Progressive Clinical Research
San Antonio, Texas
STAT Research
CABA, Argentina
Hospital Italiano de Buenos Aires
CABA, Argentina
Hospital Alemán
Capital Federal, Argentina
Centro de Investigaciones Medicas Mar del Plata
Mar del Plata, Argentina
Instituto de Especialidades de la Salud Rosario
Rosario, Argentina
Sanatorio 9 de Julio S.A.
San Miguel de Tucumán, Argentina
Holdsworth House Medical Practice
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Alfred Hospital
Melbourne, Victoria, Australia
AKH - Medical University of Vienna
Vienna, Austria
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Centre Hospitalier Universitaire de Liège
Liège, Belgium
Medical Center "Kordis"
Pleven, Bulgaria
ASMC-IPSMC-skin and Veneral Diseases
Sofia, Bulgaria
Diagnostic Consultative Center Alexandrovska
Sofia, Bulgaria
DCC "Fokus-5-LZIP" OOD
Sofia, Bulgaria
Medical Military Academy MHAT Sofia
Sofia, Bulgaria
MHAT Prof Stoyan Kirkovich AD
Stara Zagora, Bulgaria
Alberta DermaSurgery Centre
Edmonton, Alberta, Canada
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, Canada
Guelph Dermatology Research
Guelph, Ontario, Canada
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.